Exagen Inc

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exagen Inc reports robust Q1 revenue growth and strategic expansion

Exagen Inc's Q1 performance reflects strong revenue growth and improved financial outlook, driven by enhanced ASP and strategic initiatives.
Despite challenges in initial demand impact and regulatory monitoring, the company remains optimistic about future growth prospects and market positioning.
With a focus on innovation, market expansion, and operational efficiency, Exagen Inc aims to capitalize on opportunities for sustained growth and competitive advantage.

Exagen Inc reports strong Q2 performance, eyes growth through innovation

Exagen Inc's Q2 performance reflects significant improvement in financial metrics, revenue growth, and progress towards profitability, driven by increased clinical adoption and strategic initiatives.
The company's focus on innovation, market expansion, and customer engagement through new markers, biopharma contracts, and educational campaigns positions them for sustained growth and competitive advantage.
While challenges persist in achieving profitability and market acceptance, Exagen's proactive approach to addressing these hurdles and leveraging opportunities bodes well for their future success and market leadership.

Exagen Inc reports progress in revenue growth and innovation initiatives

Exagen Inc's Q3 2024 earnings call highlighted both achievements and challenges, with a focus on revenue growth, innovation, and operational improvements. The company is poised for growth with upcoming product launches and a strategic approach to enhancing the clinician experience. Challenges remain in achieving profitability and managing capacity expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Exagen Inc. (NASDAQ:XGN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded.

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis.

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a panel discussion on Tuesday, September 26th, at 8:45 AM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Start Time: 08:30 January 1, 0000 9:21 AM ET Exagen Inc. (NASDAQ:XGN ) Q2 2023 Earnings Conference Call August 07, 2023, 08:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Dustin Scaringe - William Blair Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call.

Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023.

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 43rd Annual Growth Conference, which takes place August 7-10, 2023, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer and Kamal Adawi, Exagen's Chief Financial Officer, will present on Wednesday, August 9th, at 3:00 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43r d Annual Growth Stock Conference, which takes place June 6-8, 2023, in Chicago at the Loews Chicago Hotel. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will present on Wednesday, June 7th, at 2:00 PM CT. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

Exagen Inc. (NASDAQ:XGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023. First Quarter Highlights: Delivered a record 37,312 AVISE® CTD tests in the first quarter, a 21% increase over the first quarter of 2022 and a 10% increase over the fourth quarter of 2022.

Exagen Inc. Reports First Quarter 2023 Results

The stock price of Exagen Inc (NASDAQ: XGN) fell by 14.89% after hours in the most recent trading session. This is why.

XGN Stock: 14.89% Drop After Hours Explanation

Exagen Inc. (NASDAQ:XGN ) Q4 2022 Results Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Kyle Mikson - Canaccord Dan Brennan - Cowen Paul Knight - KeyBanc Capital Markets Operator Greetings, and welcome to the Exagen Inc. Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript

Record AVISE® CTD Volume in 2022 Record AVISE® CTD Volume in 2022

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March investor conferences.

Exagen Inc. to Participate in Upcoming March Conferences

SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, UT. Management will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.

Exagen Inc. Elects Tina S. Nova, Ph.D.

Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief Operating Officer Conference Call Participants Max Masucci - Cowen & Company Griffin Soriano - William Blair Kyle Mikson - Canaccord Genuity Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript

Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Exagen Inc Stock (XGN)